69 activities found

  • go
  • add

Expert Perspectives: Lymphoma & Myeloma 2014: An International Congress on Hematologic Malignancies

Recent advances in clinical and basic research identifying underlying genetic and biological events associated with the pathology of hematologic malignancies have yielded numerous therapeutic innovations. These advancements have resulted in the discovery of new targeted therapies, the evolution of more effective treatment strategies and the determination of enhanced tools for accurate disease diagnosis and risk stratification. Recorded at Lymphoma & Myeloma 2014: An International Congress on Hematologic Malignancies, this Expert Perspectives activity provides discussion between Dr. Coleman and the Congress session Chairs for the potential of novel therapeutic and diagnostic tools to impact patients outcomes and quality of life through analysis of pertinent clinical data presented during the three day Congress.
  • Audio
  • Video
  • Text
1 CME
  • go
  • add

Webcast: Clinical Considerations for the Treatment of Mantle Cell Lymphoma, A Satellite Symposium at Lymphoma & Myeloma 2014

Clinical advances in front-line treatment of mantle cell lymphoma (MCL) over the past two decades have enhanced patient outcomes. However, even with the advances made in chemotherapy, chemo-immunotherapy and stem cell transplantation there is still no standardized front-line therapy for MCL and certain therapies can be used only in specific patient populations. Furthermore, with relapse of disease and resistance to current therapies being common in these patients, complex clinical challenges regarding disease management are prevalent. As our understanding of the biological events involved in the pathogenesis of MCL continues to develop and new therapeutic regimens and novel targeted agents are introduced into everyday clinical practice, healthcare professionals must be kept abreast of new strategies for the management of MCL and be able to evaluate the clinical implications of emerging data. Continued education, including expert guidance regarding disease pathogenesis and optimal integration of treatment regimens tailored to specific patient populations in both the front-line and relapsed/refractory setting will help enhance clinical outcomes and improvement patient quality of life.
  • Audio
  • Video
  • Text
0.75 CME
  • go
  • add

Webcast: Novel Agents versus Chemotherapy in the Front-line Treatment of Chronic Lymphocytic Leukemia, A Satellite Symposium at Lymphoma & Myeloma 2014

Chronic lymphocytic leukemia (CLL) is the most common lymphoid malignancy in the western world and has a highly variable course. Advances in diagnosis, risk assessment and front-line treatment options for newly diagnosed CLL patients are providing benefit to overall survival and progression-free survival but CLL remains an incurable disease and long-term survival of poor prognosis patients is unsatisfactory. With these concerns in mind, therapies that have shown clinical activity in the relapsed/refractory setting are currently being investigated as front-line therapies for newly diagnosed CLL. As these studies move toward fruition, clinical questions pertaining to optimal treatment strategies and integration of novel, targeted therapies in combination with antibody-based regimens, or standard chemotherapy/antibody regimens into everyday clinical practice come to light. With the potential for these combination therapies to impact the front-line CLL treatment paradigm, healthcare professionals must be kept abreast of the latest therapeutic algorithms and their impact on clinical outcomes and patient quality of life.
  • Audio
  • Video
  • Text
0.75 CME
  • go
  • add

Investigator Insights: The Therapeutic Potential of Novel PARP Inhibitors in the Clinic for Improved Management of Epithelial Ovarian Cancer

Dr. Bradley Monk discusses the novel PARP inhibitors (PARPi) in clinical development for advanced ovarian cancers and provides the clinical context for their integration into existing treatment paradigms. The biology of ovarian cancers, latest trial data with PARPi, the potential for patient selection, and the ongoing phase III clinical studies are highlighted.
  • Audio
  • Video
  • Text
0.75 CME
  • go
  • add

Expert Perspectives: Perspectives in Melanoma XVIII

Drs. John M. Kirkwood and Antoni Ribas summarize the key take-home messages on the latest advances in melanoma research discussed during the Perspectives in Melanoma XVIII Annual Meeting held in Dublin, Ireland. The newest scientific ideas on melanoma genetics and biology, screening and surveillance, BRAF and MEK inhibitor therapy, immunotherapies, and combination strategies are highlighted in a one-on-one dialogue; moreover, global access to novel melanoma drugs and insights on current practice patterns are provided.
  • Audio
  • Video
  • Text
0.5 CME
  • go
  • add

Best of the Day: from the American College of Gastroenterology 2014 Annual Scientific Meeting & Postgraduate Course

With multiple new and emerging advancements in the field of inflammatory bowel disease (IBD), and with the volume of patients continuing to increase, healthcare professionals are more challenged than ever to deliver optimal patient care. The Annual Scientific Meeting of the American College of Gastroenterology (ACG) is a leading forum where investigators and healthcare professionals come together, share their knowledge and experience, and learn about the latest advances and new clinical insights in hepatology and gastroenterology, including IBD. In this "Best of the Day" program, Dr. David T. Rubin is joined by Drs. Stephen B. Hanauer, Russell D. Cohen, and Gary R. Lichtenstein to summarize, review, and interpret the clinically significant information presented during the 2014 ACG Annual Scientific Meeting & Postgraduate Course in Philadelphia, Pennsylvania from October 17-22, 2014.
  • Text
1 CME
  • go
  • add

Best of the Day: from the 2014 European Society of Medical Oncology (ESMO) Congress - Melanoma

This ESMO “Best of the Day” features a one-on-one interview between Dr Axel Grothey and Dr Caroline Robert.. Highlights include: late-breaking updates on the Phase II Co-BRIM trial, an overview of anti-PD-1/PD-L1 antibodies approved and in development, and emerging therapies for BRAF V600E/K mutation-positive melanoma.
  • Audio
  • Video
  • Text
0 CME
  • go
  • add

Best of the Day: from the 2014 European Society of Medical Oncology (ESMO) Congress - Breast Cancer

In this "Best of the Day" presentation from ESMO 2014, Dr. Javier Cortes reviews the latest advances, clinical trial updates, and late-breaking news presented during this year's breast cancer sessions. Highlights include final overall survival data from the phase III CLEOPATRA trial for patients with HER2-positive metastatic breast cancer, updates to the phase III IMELDA and TANIA trials, providing an understanding of the benefits of bevacizumab maintenance therapy for patients with HER2-negative metastatic breast cancer, and characterization of breast cancer tumors.
  • Audio
  • Video
  • Text
0 CME
  • go
  • add

Best of the Day: from the 2014 European Society of Medical Oncology (ESMO) Congress - Gastrointestinal Cancer

In this "Best of the Day" interview from ESMO 2014, Dr. Axel Grothey is joined by Dr. Florian Lordick to review the latest advances, clinical trial updates, and late-breaking news presented during this year's gastrointestinal malignancies sessions. Discussion highlights include new and emerging therapies for gastric, pancreatic, and colorectal cancers; immunotherapy for GI malignancies; and antiangiogenic agents for advanced GI malignancies.
  • Audio
  • Video
  • Text
0 CME
  • go
  • add

Best of the Day: from the 2014 European Society of Medical Oncology (ESMO) Congress - Genitourinary Cancers

In this "Best of the Day" interview from ESMO 2014, Dr. Ramaswamy Govindan is joined by Dr. Cora Sternberg to review the latest advances, clinical trial updates, and late-breaking news presented during this year's genitourinary cancer sessions. Discussion highlights include practice-changing results from the CHAARTED prostate cancer trial; updates on the PREVAIL, COUGAR 302, and AFFIRM trials; and an update on androgen receptor splice variant AR-V7's status as a biomarker to predict resistance to androgen receptor targeting agents.
  • Audio
  • Video
  • Text
0 CME